← Eichor
Condition: Myeloid Hematological Malignancies Synced from ClinicalTrials.gov · July 30, 2026

Recruiting studies: Myeloid Hematological Malignancies

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Romiplostim N01 for Platelet Recovery After Haploidentical HSCT
Phase 1 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07321626A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia:
Phase 1/Phase 2 · 2 location(s) · Jacqueline Garcia, MD · NCT07148180Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and
Phase 1/Phase 2 · 26 location(s) · Sellas Life Sciences Group · NCT04588922Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633Germline Testing for Predisposition to Myeloid Malignancies
NA · 1 location(s) · Christopher Reilly · NCT07112287Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06013423Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/Phase 2 · 39 location(s) · CellCentric Ltd. · NCT04068597Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dend
Phase 1/Phase 2 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06006403Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 45 location(s) · Kura Oncology, Inc. · NCT06001788Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen University General Hospital · NCT07584889Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Phase 3 · 106 location(s) · Kura Oncology, Inc. · NCT07007312CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
EARLY_Phase 1 · 1 location(s) · Institute of Hematology and Blood Transfusion, Czech Republi · NCT06765876National Longitudinal Cohort of Hematological Diseases
Phase N/A · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT04645199Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease
NA · 7 location(s) · Christoffer Johansen · NCT05444348Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
Phase 2 · 4 location(s) · Brian Jonas · NCT04905810Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Phase 1 · 1 location(s) · Fox Chase Cancer Center · NCT06218628A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Phase 1 · 12 location(s) · Orca Biosystems, Inc. · NCT03802695HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chro
Phase N/A · 4 location(s) · Hikma Pharmaceuticals LLC · NCT05282108Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors
NA · 1 location(s) · European Institute of Oncology · NCT06785077Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Hangzhou Weben Pharma Co., Ltd · NCT07014449Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Phase 1 · 1 location(s) · University of Chicago · NCT03326310Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment o
Phase 1 · 2 location(s) · Catherine Bollard · NCT02203903Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04033302SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplas
Phase 1 · 3 location(s) · Dana-Farber Cancer Institute · NCT03113643A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
Phase 1 · 1 location(s) · Nanjing Chia-tai Tianqing Pharmaceutical · NCT06049667Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Phase 2 · 1 location(s) · University of Florida · NCT05800210MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantati
Phase 1 · 1 location(s) · Sawa Ito, MD · NCT07565220MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.